All News
Juvenile Arthritis at Risk for Coronary Artery Disease
Arthritis Care & Research reports that juvenile arthritis (JA) patients may have a higher risk if coronary artery disease (CAD) in adulthood.
Read ArticleRheumNow Podcast – When You’re Hot You’re Hot (10.11.19)
Dr. Jack Cush delivers select commentary on select news and journal articles from the past week on RheumNow.com.
Read ArticleRheumNow Podcast is up! When youre hot youre hot! Watch it on youtube>> https://t.co/GlqMzjUnhE or listen to the podcast in your car on iTues, Apple podcast or on Stitcher or SoundCloud>> https://t.co/a1zE7VXtog
Dr. John Cush RheumNow ( View Tweet)
Long Delays for Inflammatory Arthritis Patients
The National Rheumatoid Arthritis Society's (NRAS) annual audit has identified significant treatment delays for patients with suspected early inflammatory arthritis could result in unnecessary harm.
Read ArticleSprifermin Benefits Cartilage Loss but not Symptoms in Knee Osteoarthritis
Intra-articular sprifermin given to patients with symptomatic and radiographic knee osteoarthritis has been shown to significantly improve total femorotibial joint cartilage thickness after 2 years, but without significant clinical benefits. Which begs the question, why is there a disconnect between radiographic disease modification (cartilage thickness) and symptomatic improvement?
Read ArticleAntibiotics Increase Rheumatoid Risk - Again
Another UK study has suggested that prior use of antibiotics increases the risk of developing rheumatoid arthritis (RA).
Read ArticleRheumNow Podcast – Women Take Over Rheumatology (10.4.19)
Dr. Jack Cush reviews the News and Journal Reports from this week on RheumNow.com.
Read ArticleAnakinra Use in Hospitalized Gout Patients
While the efficacy and safety of interleukin 1 (IL-1) inhibitors (e.g., anakinra) in the acute management of gout and pseudogout has been repeatedly shown, the cost efficacy of such biologic therapy has rendered it impractical for most. A new retrospective study has shown that IL-1 inhibitors may be effective and appropriate for some medically complex, hospitalized patients with acute gout or calcium pyrophosphate crystal arthritis.
Read ArticleRheumNow Podcast – Cancer Risk in Systemic Sclerosis (9.27.19)
Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com.
Read ArticlePersistent Inflammatory Arthritis After Immune Checkpoint Inhibitors
Braaten and colleagues from Johns Hopkins School of Medicine have reported their experience with chronic inflammatory arthritis induced by immune checkpoint inhibitor therapies, showing that in some, inflammatory arthritis persists after the immunotherapy has been discontinued.
Nucala (mepolizumab) was approved in 2015 for severe eosinophilic asthma, and in 2017 for EGPA (Churg Strauss). The FDA has now approved it for use in Six to 11-Year-Old Children with Severe Eosinophilic Asthma https://t.co/orAaFCkR92
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – The End of Arthritis (9.13.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read ArticleTwo vs. Four Weeks of Antibiotic Therapy in Septic Arthritis
A prospective trial has shown that 2 weeks of antibiotic therapy is as effective as 4 weeks of antibiotic therapy, with similar outcomes but shorter hospital stays.
Read ArticleBimekizumab Add-on Therapy in Rheumatoid Arthritis
Bimekizumab is a dual inhibitor of IL-17A and IL-17F that has been shown to be effective in psoriasis and psoriatic arthritis. A proof-of-concept study shows that giving bimekizumab to rheumatoid arthritis patients not adequately controlled by certolizumab pegol resulted in a rapid decrease in disease activity achieved after 12 weeks of treatment. These findings are novel as anti-IL-17 monoclonal antibody therapy has previously been shown to be ineffective in RA.
Read Article74 Percent of Rheumatoid Arthritis Patients Dissatisfied with Treatment
CreakyJoints has completed a 258 patient survey showing that nearly three-fourths of people with rheumatoid arthritis (RA) have expressed dissatisfaction with their treatments, including conventional (csDMARDs) and biologic Disease Modifying Antirheumatic Drugs (bDMARDs).
Read ArticleRA Women are Less Likely to Breastfeed
A large pregnancy registry has published their results showing rheumatoid arthritis (RA) patients who become pregnant are less likely to breastfeed compared to non-RA women from the general population, with many women stopping breastfeeding so that they could start medication, even though many of
Read ArticleRespiratory Risks Not Increased in RA Patients with COPD
An insurance claims based study of RA patients with COPD shows that biologics do not have an increased rate of respiratory events compared to those on conventional DMARDs.
A real world cohort of RA patients with COPD was drawn from US-based MarketScan databases. Patients on biologic DMARDs and/or targeted synthetic DMARDs (tsDMARDs) were propensity matched to those on conventional synthetic DMARDs (csDMARDs).
Tocilizumab Shows No Increase in Cardiovascular Risk
The ENTRACTE trial examined the risk for major adverse cardiovascular events (MACE) in RA patients and found no increased risk of MACE in patients treated with tocilizumab (TCZ) versus etanercept (ETN).
Read ArticleNumber of Prior DMARDs Portends Poorer Outcomes
Detailed analysis of two clinical trials in RA has shown that clinical responses decrease as the disease duration and number of prior DMARDs increase.
The associations between disease duration and number of prior DMARDs and response to therapy were assessed using data from two randomised controlled trials in patients with established RA (mean duration, 11 years) receiving adalimumab+methotrexate.
RheumNow Podcast - I Wanna New Drug (8-30-19)
Dr. Jack Cush vents on choosing new therapies in rheumatoid arthritis.
Read Article